Document is current
Any future updates will be listed below
-
Authors
Hagström, Emil
Ortsäter, Gustaf
Almlöf, Emil
Vasilevska, Marija
Leósdóttir, Margrét
Wettermark, Björn
Banefelt, Jonas
Larsen, Anders Peter
- License Information
-
More Information
Article History
Received: 27 May 2025
Accepted: 13 November 2025
First Online: 11 February 2026
Declarations
:
: Emil Hagström has received institutional grants from Pfizer, NovoNordisk and Amgen. He has also obtained payment/honoraria from Amgen, NovoNordisk, Bayer and AstraZeneca for lectures, presentations, participation in advisory board etc. Emil Almlöf is an employee of Novartis. Anders Peter Larsen is an employee of Novartis. Gustaf Ortsäter is an employee of Quantify Research and owns Quantify Research stocks and stock options. Jonas Banefelt is an employee of Quantify Research and owns Quantify Research stocks and stock options. Marija Vasilevska is an employee of Quantify Research. Quantify Research AB provides consulting and other research services to pharmaceutical, medical device, and related organizations. Quantify Research AB received funding from Novartis AB to conduct this study and for the development of this manuscript. Margrét Leósdóttir has received institutional grants and honoraria from Amarin, Amgen, AstraZeneca, Bonnier Health Care, NovoNordisk and Sanofi outside the submitted work. Björn Wettermark has no conflict of interest to declare.
